Clinical Trials | October 16, 2025
Merck’s DOR/ISL regimen shows minimal impact on weight and lipids in phase 3 HIV studies
These findings follow positive Phase 3 results presented earlier this year
These findings follow positive Phase 3 results presented earlier this year
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
Subscribe To Our Newsletter & Stay Updated
